Semaglutide linked to optic nerve risk

These are diabetes and weight-loss drugs, but the news is about the optic nerve — the cable that carries visual information from the eye to the brain. That matters because damage there can mean sudden, sometimes permanent vision loss. The gap has been that doctors were seeing scattered case reports without knowing whether this was a real drug-safety signal or just coincidence. Now a very large electronic-health-record study, plus a newer veterans analysis, makes the concern harder to brush off. (jamanetwork.com) ### What exactly is the eye problem here? The main condition getting attention is NAION — nonarteritic anterior ischemic optic neuropathy. Basically, the front part of the optic nerve loses blood flow and vision drops suddenly, usually without pain. It is one of the most common acute optic-nerve injuries in older adults, and there is no proven treatment that reliably reverses it once it happens. (ajmc.com) ### What changed with this new study? The big update came in August 2025 in JAMA Network Open. Researchers emulated target trials in a nationwide US EHR database, starting with 1,511,637 eligible patients with type 2 diabetes and then building a matched cohort of 159,398 people. Compared with other d(ajmc.com)ders over 2 years, but the paper was explicit that the overall risk stayed low. (jamanetwork.com) ### How big is the risk in plain English? Small in absolute terms, but not zero. The cleanest concrete number comes from a March 2026 JAMA Ophthalmology brief in US veterans: semaglutide initiators had about a 2-fold higher NAION risk than people starting an SGLT2 inhibitor, with cumulative risks of 0.29% versus 0.13% o(jamanetwork.com)hen the event is rare. (jamanetwork.com) ### Didn’t this start with just a few weird cases? Yes — and that is important context. A January 2025 JAMA Ophthalmology case series described 9 patients taking semaglutide or tirzepatide: 7 had NAION, 1 had papillitis, and 1 had paracentral acute middle maculopathy. A case series cannot prove causation, but it is often how a safety problem first shows up — like smoke before anyone confirms the fire. (jamanetwork.com) ### Do doctors think the drug itself is toxic to the nerve? Not necessarily. One leading idea is that rapid glucose improvement may stress vulnerable eyes in some patients, rather than the drug directly poisoning the optic nerve. That is also why the papers are careful — they talk about association, not proof. Observa(jamanetwork.com)atients who got one drug versus another. (jamanetwork.com) ### Should patients stop these drugs? Not on the basis of this alone. These medicines have major benefits for blood sugar, weight, and in some cases cardiovascular risk. The current labels already warn about vision changes and diabetic retinopathy monitoring in some settings, but they do not amount to a blanket “every(jamanetwork.com) field cut, or abrupt vision loss needs urgent eye evaluation. (accessdata.fda.gov) ### What are eye doctors likely to do differently? Mostly, ask better medication-history questions. The studies do not support routine screening of every person on semaglutide or tirzepatide, but they do support documenting GLP-1 or GIP drug exposure when someone shows up with optic neuropathy, disc swelling, (accessdata.fda.gov) change. (ajmc.com) ### Bottom line? The story is not “Ozempic causes blindness.” It is that a rare but serious optic-nerve complication now has enough signal behind it that doctors should take visual symptoms on these drugs seriously — and fast. (jamanetwork.com)